Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database

Cancer

Volumn 119, Issue 20, 2013, Pages 3672-3679

  Castillo, Jorge J ^a   Winer, Eric S ^a   Olszewski, Adam J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Burkitt lymphoma; epidemiology; prognostic factors; race; rituximab; SEER

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; BURKITT LYMPHOMA; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; ETHNICITY; FEMALE; GASTROINTESTINAL TRACT; HEAD; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NECK; NEGRO; PRIORITY JOURNAL; RACE; RISK ASSESSMENT; SCORING SYSTEM; UNITED STATES;

BURKITT LYMPHOMA; EPIDEMIOLOGY; PROGNOSTIC FACTORS; RACE; RITUXIMAB; SEER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BURKITT LYMPHOMA; COHORT STUDIES; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RHODE ISLAND; SEER PROGRAM; SURVIVAL RATE; YOUNG ADULT;

EID: 84885189977     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28264     Document Type: Article

References (35)

1. Blum KA, Lozanski G, Byrd JC,. Adult Burkitt leukemia and lymphoma. Blood. 2004; 104: 3009-3020. (Pubitemid 39507113)
2. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008; 112: 2248-2260.
3. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002; 13: 1264-1274. (Pubitemid 34960136)
4. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002; 94: 1492-1499. (Pubitemid 34212643)
5. Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA,. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol. 1986; 4: 847-858. (Pubitemid 16080937)
6. Magrath IT, Janus C, Edwards BK, et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984; 63: 1102-1111. (Pubitemid 14100910)
7. Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011; 22: 1859-1864.
8. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106: 1569-1580.
9. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying)-Linked To County Attributes-Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission; 2012.
10. Surveillance Research Program, National Cancer Institute SEER*Stat software, version 8.0.2; 2013.
11. NAACCR Race and Ethnicity Work Group. NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2.2.1]. http://www.naaccr.org/LinkClick.aspx?fileticket= 6E20OT41TcA%3d Revised September 12, 2011. Accessed April 26, 2012.
12. Hakulinen T, Seppa K, Lambert PC,. Choosing the relative survival method for cancer survival estimation. Eur J Cancer. 2011; 47: 2202-2210.
13. Nelson CP, Lambert PC, Squire IB, Jones DR,. Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med. 2007; 26: 5486-5498. (Pubitemid 351193576)
14. Eloranta S, Adolfsson J, Lambert PC, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control. 2013; 24: 505-515.
15. Cronin KA, Feuer EJ,. Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med. 2000; 19: 1729-1740. (Pubitemid 30436059)
16. Andersson TM, Dickman PW, Eloranta S, Lambert PC,. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol. 2011; 11: 96.
17. Cronin K, Mariotto A, Scoppa S, Green D, Clegg L,. Differences Between Brenner et al. and NCI Methods for Calculating Period Survival. Technical Report 2003-02. Statistical Research and Applications Branch, National Cancer Institute [serial online] 2003. http://surveillance.cancer.gov/reports. Accessed February 19, 2013.
18. Brenner H, Gefeller O, Hakulinen T,. Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer. 2004; 40: 326-335. (Pubitemid 38121268)
19. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24: 3121-3127. (Pubitemid 46638950)
20. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-likechemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-391.
21. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010; 116: 2040-2045.
22. Ribrag V, Koscielny S, Bouabdallah K, et al. Addition of Rituximab Improves Outcome of HIV Negative Patients with Burkitt Lymphoma Treated with the Lmba Protocol: Results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 Protocol. (IGR sponsored LMBA02, NCT00180882). American Society of Hematology Annual Meeting Abstracts. 2012; 120: Abstract 685.
23. Evens AM, Islam N, Carson KR, et al. A phase 2 clinical trial adding rituximab to CODOX-M/IVAC for untreated Burkitts lymphoma: correlative analysis of serum and CSF rituximab levels. American Society of Hematology Annual Meeting Abstracts. 2012; 120: Abstract 1640.
24. Kelly JL, Toothaker SR, Ciminello L, et al. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma. 2009; 9: 307-310.
25. Cairo MS, Sposto R, Perkins SL, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol. 2003; 120: 660-670. (Pubitemid 36255868)
26. Shenoy PJ, Malik N, Nooka A, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011; 117: 2530-2540.
27. Flowers CR, Fedewa SA, Chen AY, et al. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1520-1530.
28. Kent EE, Morris RA, Largent JA, Ziogas A, Sender LS, Anton-Culver H,. Socioeconomic impacts on survival differ by race/ethnicity among adolescents and young adults with non-Hodgkin's lymphoma. J Cancer Epidemiol. 2010; 2010: 824691.
29. Keegan TH, Clarke CA, Chang ET, Shema SJ, Glaser SL,. Disparities in survival after Hodgkin lymphoma: a population-based study. Cancer CausesControl. 2009; 20: 1881-1892.
30. Costa LJ, Xavier AC, Wahlquist AE, Hill EG,. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood. 2013; 121: 4861-4866.
31. Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA,. Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev. 2004; 13: 138-143. (Pubitemid 38116631)
32. Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA,. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006; 15: 630-638.
33. Wasterlid T, Jonsson B, Hagberg H, Jerkeman M,. Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leuk Lymphoma. 2011; 52: 2090-2096.
34. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008; 113: 117-125. (Pubitemid 351976392)
35. Rodrigo JA, Hicks LK, Cheung MC, et al. HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era. Adv Hematol. 2012; 2012: 735392.